APOE and Alzheimer disease: Moreover, a number of studies have suggested differences in magnitude of the effect of APOE during the entire period of AD risk, with APOE ε4 reaching its peak effect between the age of 60–79 years (Bickeböller et al., 1997, Bonham et al., 2016).